These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 17874856)

  • 21. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Bijie H; Dzierzanowska D; Klimko NN; Letscher-Bru V; Lisalova M; Muehlethaler K; Rennison C; Zaidi M;
    J Clin Microbiol; 2009 Jan; 47(1):117-23. PubMed ID: 19005141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
    J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.
    Drago M; Scaltrito MM; Morace G;
    Eur J Clin Microbiol Infect Dis; 2004 Aug; 23(8):619-24. PubMed ID: 15258831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [In vitro activity of voriconazole against yeast and algae isolates according to new resistance pattern cut-off points].
    Pemán J; Cantón E; Calabuig E; Bosch M; Valentí A; Viudes A; Gobernado M
    Rev Esp Quimioter; 2006 Mar; 19(1):21-33. PubMed ID: 16688288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.
    Marco F; Pfaller MA; Messer SA; Jones RN
    Med Mycol; 1998 Dec; 36(6):433-6. PubMed ID: 10206756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Voriconazole - applications and perspectives].
    Ruhnke M
    Mycoses; 2002; 45 Suppl 3():42-7. PubMed ID: 12690971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [In vitro antifungal activity of micafungin].
    Quindós G; Eraso E; Javier Carrillo-Muñoz A; Cantón E; Pemán J
    Rev Iberoam Micol; 2009 Mar; 26(1):35-41. PubMed ID: 19463275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.
    Pfaller MA; Messer SA; Georgopapadakou N; Martell LA; Besterman JM; Diekema DJ
    J Clin Microbiol; 2009 Dec; 47(12):3797-804. PubMed ID: 19794038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Voriconazole activity against clinical yeast isolates: a multicentre Italian study.
    Morace G; Polonelli L;
    Int J Antimicrob Agents; 2005 Sep; 26(3):247-53. PubMed ID: 16051469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic/pharmacodynamic profile of voriconazole.
    Theuretzbacher U; Ihle F; Derendorf H
    Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacology and clinical use of voriconazole.
    Thompson GR; Lewis JS
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):83-94. PubMed ID: 19947892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
    Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
    Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.
    Johnson EM; Szekely A; Warnock DW
    J Antimicrob Chemother; 1998 Dec; 42(6):741-5. PubMed ID: 10052897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [In vitro activity of voriconazole and other antifungal agents against clinical isolates of 138 Candida spp].
    Ricciardi AM; Ricciardi R; Danzi M; Mungiguerra M; Pisano L; Marino A
    Infez Med; 2009 Mar; 17(1):24-7. PubMed ID: 19359821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antifungal activity of the new azole UK-109, 496 (voriconazole).
    Kappe R
    Mycoses; 1999; 42 Suppl 2():83-6. PubMed ID: 10865910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of voriconazole pharmacodynamics using time-kill methodology.
    Klepser ME; Malone D; Lewis RE; Ernst EJ; Pfaller MA
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1917-20. PubMed ID: 10858354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens.
    Marangon FB; Miller D; Giaconi JA; Alfonso EC
    Am J Ophthalmol; 2004 May; 137(5):820-5. PubMed ID: 15126145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.